Dr. Ning Xie 谢宁
Chief Physician
Department of Medical Oncology for Breast Cancer, Hunan Cancer Hospital, Changsha
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment of breast cancer, including endocrine therapy, chemotherapy, molecular targeted therapy, and immunotherapy.
Dr. Xie is Deputy Director of the Department and holds a medical doctorate. A visiting scholar at Siena University Hospital in Italy, Dr. Xie has years of experience in clinical diagnosis and treatment of breast cancer. Dr. Xie has led research projects funded by the Hunan Provincial Natural Science Foundation and other agencies.
Professional roles
- Member, Breast Cancer Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Standing Committee Member, Young Experts Committee, Chinese Society of Clinical Oncology (CSCO)
- Deputy Convener, Young Expert Group, International Medical Exchange Committee, China Anti-Cancer Association
- Vice Chair, Breast Cancer Professional Committee, Hunan International Medical Exchange Promotion Association
Name order: in Chinese the family name comes first (Xie Ning). Papers usually list the name as Ning Xie or Xie N.
Selected publications
39 papers on PubMed matched by name and affiliation; 11 as first or senior author since 2016. Most recent first- or senior-author papers:
- Aesthetic Plast Surg, 2026 (senior author): Correction: From Etiology to Aesthetic Surgery: Mapping Knowledge Domains and Emerging Trends in Gynecomastia Research: 35-Year Bibliometric Analysis. PubMed 42788994
- Aesthetic Plast Surg, 2026 (senior author): From Etiology to Aesthetic Surgery: Mapping Knowledge Domains and Emerging Trends in Gynecomastia Research: 35-Year Bibliometric Analysis. PubMed 42414646
- Breast Cancer Res Treat, 2026 (senior author): Machine learning and cox model-based prediction of CDK4/6 inhibitor outcomes in HR+/HER2 - metastatic breast cancer: a multicenter real-world study. PubMed 42536225
- Health Econ Rev, 2026 (senior author): Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer with PD-L1-positive: a cost-effectiveness analysis. PubMed 42900283
- Transl Breast Cancer Res, 2026 (senior author): Real-world efficacy and prognostic factors of CDK4/6 inhibitors in HR(+)/HER2(-) metastatic breast cancer: a multicenter retrospective study from the Dongting Lake region of China. PubMed 41675004
- J Clin Lab Anal, 2024 (first author): Interpretable Machine Learning Algorithms Identify Inetetamab-Mediated Metabolic Signatures and Biomarkers in Treating Breast Cancer. PubMed 39569974
- Ann Transl Med, 2022 (first author): Artificial intelligence scale-invariant feature transform algorithm-based system to improve the calculation accuracy of Ki-67 index in invasive breast cancer: a multicenter retrospective study. PubMed 36330383
- BMJ Open, 2022 (first author): Impact of surgical management of primary tumors in stage IV breast cancer patients: a retrospective observational study based on SEER database. PubMed 35105583
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion